Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Trial Profile

A Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospasm-related Morbidity and All-cause Mortality in Adult Patients With Aneurysmal Subarachnoid Hemorrhage Treated by Surgical Clipping

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Dec 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clazosentan (Primary)
  • Indications Cerebral vasospasm
  • Focus Registrational; Therapeutic Use
  • Acronyms CONSCIOUS-2
  • Sponsors Actelion Pharmaceuticals

Most Recent Events

  • 23 Nov 2020 According to an Idorsia Pharmaceuticals Media Release, the company expects to file New Drug Application (NDA) with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in the first half of 2021 and make the full results available through scientific publication.
  • 23 Nov 2020 According to an Idorsia Pharmaceuticals Media Release, further analysis is ongoing including additional pooled analysis of data from CONSCIOUS-2 and CONSCIOUS-3 studies.
  • 23 Nov 2020 Positive top-line results from pre-planned pooled analysis from CONSCIOUS-2 and CONSCIOUS-3 studies presented in an Idorsia Pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top